Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 9Recruiting 8Completed 2Terminated 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1

Interventions

pembrolizumab 28Carboplatin 18Cisplatin 15Nivolumab 13Pemetrexed 12Paclitaxel 11Specimen Handling 10Ipilimumab 10Gemcitabine 10venetoclax 8durvalumab 8atezolizumab 8Radiotherapy 8Radiosurgery 8Magnetic Resonance Spectroscopy 8Docetaxel 7Cyclophosphamide 7Biopsy 7fludarabine 6enzalutamide 6Bevacizumab 6tislelizumab 5tazemetostat 5X-Rays 5Trastuzumab 5Surveys and Questionnaires 5Practice Guidelines as Topic 5Interviews as Topic 5Injections 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × alectinib × 90 days × Clear all
NCT03737994 2026-04-23

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
10 enrolled 17 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡